New ALS scholarship supports US students facing financial barriers
The Everylife Foundation for Rare Diseases is offering a new scholarship for students from the amyotrophic lateral sclerosis…
Articles by Margarida Maia, PhD
Transposon’s TPN-101 selected for testing in HEALEY ALS trial
Oral small molecule TPN-101 has been selected for testing in amyotrophic lateral sclerosis (ALS) as part of the HEALEY ALS platform…
FDA clears Phase 3b trial of NurOwn for ALS
The U.S. Food and Drug Administration (FDA) has cleared a Phase 3b clinical trial to test Brainstorm Cell Therapeutics’ cell-based…
Bacteria mix to aid gut microbiome may slow ALS progression
MaaT033, an oral therapy aiming to restore balance to the collection of bacteria and other microbes in the gut, was…
Young investigators receive MGH awards for ALS research
Three researchers at Massachusetts General Hospital (MGH) have received 2025 MGH ALS Young Investigator Awards for their research on genetic…
Real-world Radicava use in ALS tied to unexpected side effects: Data
The real-world use of Radicava (edaravone), an infusion treatment approved for amyotrophic lateral sclerosis (ALS), may cause serious…
Groups ask lawmakers to preserve National ALS Registry funding
ALS groups are asking lawmakers to preserve federal funding for the National ALS Registry and National ALS Biorepository, the first…
Brain-computer interface to restore speech named award winner
A neurosurgeon and his team from the University of California (UC) Davis Health have won The Herbert Pardes Clinical Research…
RNS60 safe, well tolerated in EAP for advanced ALS
RNS60 was well tolerated when inhaled twice daily at home as part of an expanded access program (EAP), and it…
AAN 2025: PrimeC reduces miRNAs linked to ALS progression
Neurosense Therapeutics’ oral therapy PrimeC significantly reduces blood levels of miRNAs — molecules involved in regulating gene activity — associated…